← Back to patent-cliff list
Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine)
Tier C — Watch / tradeRosuvastatin liposome encapsulated therapy (Beijing Inno Medicine)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CD44, HMGCR
Indications (approved)：Coronary artery lesion, Atherosclerosis, Cerebrovascular disease, Erectile dysfunction
Regional status
US
Phase II
2025-12-11
EU
-
China
Phase II
2023-10-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine)?
Approved indications include: Coronary artery lesion, Atherosclerosis, Cerebrovascular disease, Erectile dysfunction.
When does the Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine) patent expire?
No public expiry year is available for Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine) yet; this page updates once verified.
How do I get a quote for Rosuvastatin liposome encapsulated therapy (Beijing Inno Medicine) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02